etrasimod: Clinical Trials

12 completed, 5 terminated, 4 active not recruiting, 4 recruiting. 16 Phase 2, 7 Phase 3, 2 Phase 1, 1 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	16	Completed 7, Terminated 5, Recruiting 3, Withdrawn 1
Phase 3	7	Completed 3, Terminated 2, Active not recruiting 1, Unknown 1
Phase 1	2	Completed 2
Phase 4	1	Not yet recruiting 1

Follow etrasimod: new trials by email Literature Review of etrasimod trials Research Report on etrasimod

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC Etrasimod, mesalazine - Etrasimod, Mesalazine	Phase 4	Not yet recruiting	Sir Run Run Shaw Hospital	320	2026-07-31	2026-08-24
A National Multicenter Study of Etrasimod for the Treatment of Patients With Active UC Etrasimod - Ulcerative Colitis (UC)		Not yet recruiting	Tang-Du Hospital	500	2026-07-15	2026-07-15
Etrasimod as Prevention of Pouchitis etrasimod, Placebo - Pouchitis	Phase 2	Recruiting	Maia Kayal	40	2026-07-01	2026-09-21
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis Etrasimod - Colitis, Ulcerative	Phase 2	Recruiting	Pfizer	24	2026-05-28	2026-10-26
An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis Velsipity - Ulcerative Colitis (UC)		Active not recruiting	Pfizer	1	2026-04-27	2026-09-04
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis		Active not recruiting	Pfizer	4000	2026-04-01	2026-10-15
Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis Etrasimod, Placebo, Corticosteroids - Immune Checkpoint Inhibitor-Related Diarrhea and Colitis	Phase 2	Withdrawn	Yale University		2026-01-01	2026-01-14
A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Women Etrasimod - Healthy Participant	Phase 1	Completed	Pfizer	8	2025-08-07	2026-10-20
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis Etrasimod - Colitis, Ulcerative		Recruiting	Pfizer	300	2024-09-17	2026-10-26
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis Etrasimod - Colitis, Ulcerative		Active not recruiting	Pfizer	360	2024-05-08	2026-10-30
A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants Etrasimod Immediate Release (IR) - Healthy Participants	Phase 1	Completed	Pfizer	8	2023-12-20	2025-03-24
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified	Phase 2 / Phase 3	Terminated	Pfizer	58	2023-01-18	2025-05-08
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis Etrasimod - Ulcerative Colitis	Phase 2	Recruiting	Pfizer	36	2022-12-16	2026-10-27
Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis Etrasimod, Placebo - Ulcerative Colitis	Phase 2	Completed	Pfizer	54	2021-09-10	2024-10-29
Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis Etrasimod, Placebo - Ulcerative Colitis	Phase 2	Completed	Pfizer	234	2021-04-12	2025-07-15
Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN) Etrasimod, Placebo - Ulcerative Colitis	Phase 3	Completed	Pfizer	42	2020-12-25	2023-10-16
A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis Etrasimod, Placebo - Eosinophilic Esophagitis	Phase 2	Completed	Pfizer	108	2020-12-15	2024-05-06
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis Etrasimod, Placebo - Ulcerative Colitis	Phase 3	Completed	Arena Pharmaceuticals	354	2020-09-15	2022-12-21
Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata Etrasimod, Placebo - Alopecia Areata	Phase 2	Completed	Pfizer	80	2020-07-29	2024-06-26
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease Etrasimod, Placebo - Crohn's Disease	Phase 2 / Phase 3	Terminated	Pfizer	379	2020-01-06	2026-07-01

Showing 20 of 30. Sign in to see all of them.

Conditions studied

Colitis, Ulcerative (17)  ·  Colitis (2)  ·  Dermatitis, Atopic (2)  ·  Inflammatory Bowel Diseases (2)  ·  Alopecia (1)  ·  Alopecia Areata (1)  ·  Crohn Disease (1)  ·  Eczema (1)  ·  Eosinophilic Esophagitis (1)  ·  Liver Cirrhosis, Biliary (1)  ·  Pouchitis (1)  ·  Pyoderma Gangrenosum (1)  ·  Ulcer (1)

Sponsors

Pfizer (17)  ·  Arena Pharmaceuticals (8)  ·  Everstar Therapeutics Limited (1)  ·  Maia Kayal (1)  ·  Sir Run Run Shaw Hospital (1)  ·  Tang-Du Hospital (1)  ·  Yale University (1)

Countries

United States (17)  ·  Australia (12)  ·  Canada (12)  ·  Belgium (11)  ·  Germany (11)  ·  Poland (10)  ·  Spain (9)  ·  United Kingdom (9)  ·  Czechia (8)  ·  France (8)  ·  Israel (8)  ·  Japan (8)  ·  Bulgaria (7)  ·  Hungary (7)  ·  Russia (7)

Top investigators

Arena CT.gov Administrator (7)  ·  Harriet Kluger, MD (1)  ·  Kaichun Wu (1)  ·  Maia Kayal, MD (1)

Results publications

PMID 39778975, PMID 39575597, PMID 42248437, PMID 36871574, PMID 39526078, PMID 38613425, PMID 38700040, PMID 38877972, PMID 39089519, PMID 39306680, PMID 39326009, PMID 39671695, PMID 39878434, PMID 39891572, PMID 40036804, PMID 40184206, PMID 40618942, PMID 40889900, PMID 41043449, PMID 41655066, PMID 42523912, PMID 42864953, PMID 31711921, PMID 38245818, PMID 40145547, PMID 40275818, PMID 40381637, PMID 41448713, PMID 42542725, PMID 42848715

NIH funding

2018 (2), 2025 (2), 2015 (1), 2023 (1)